Daniel Kotz1, Jamie Brown, Robert West. 1. Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, PO Box 616, 6200 MD Maastricht, The Netherlands. d.kotz@maastrichtuniversity.nl.
Abstract
BACKGROUND: It is important to know the comparative effectiveness of varenicline and nicotine replacement therapy (NRT) for smoking cessation when prescribed under routine circumstances and in the general population. Previous estimates relied on cross-sectional data. The objective of the current study was to use longitudinal data to compare the abstinence rates of smokers trying to stop having used varenicline versus NRT on prescription (Rx) when provided with minimal professional support in the general population while adjusting for key potential confounders. METHODS: Prospective cohort study in 270 adults who participated in a household survey, smoked at baseline, responded to the 6-month follow-up survey, and made at least one quit attempt between the two measurements with either varenicline or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported abstinence up to the time of the survey, adjusted for key potential confounders including cigarette dependence (measured at baseline). RESULTS: Users of varenicline were younger, reported more time spent with urges to smoke at baseline, and were less likely to stop abruptly during their last quit attempt (all p < 0.01). The adjusted odds of abstinence in users of varenicline were 3.83 (95% CI = 1.88-7.77) times higher compared with users of NRT Rx. CONCLUSIONS: Varenicline use with minimal professional support in the general population of smokers appears more effective than NRT Rx in achieving abstinence.
BACKGROUND: It is important to know the comparative effectiveness of varenicline and nicotine replacement therapy (NRT) for smoking cessation when prescribed under routine circumstances and in the general population. Previous estimates relied on cross-sectional data. The objective of the current study was to use longitudinal data to compare the abstinence rates of smokers trying to stop having used varenicline versus NRT on prescription (Rx) when provided with minimal professional support in the general population while adjusting for key potential confounders. METHODS: Prospective cohort study in 270 adults who participated in a household survey, smoked at baseline, responded to the 6-month follow-up survey, and made at least one quit attempt between the two measurements with either varenicline or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported abstinence up to the time of the survey, adjusted for key potential confounders including cigarette dependence (measured at baseline). RESULTS: Users of varenicline were younger, reported more time spent with urges to smoke at baseline, and were less likely to stop abruptly during their last quit attempt (all p < 0.01). The adjusted odds of abstinence in users of varenicline were 3.83 (95% CI = 1.88-7.77) times higher compared with users of NRT Rx. CONCLUSIONS: Varenicline use with minimal professional support in the general population of smokers appears more effective than NRT Rx in achieving abstinence.
Authors: Laura L Biazzo; Desireé B Froshaug; Todd S Harwell; Heather N Beck; Cynthia Haugland; Stacy L Campbell; Steven D Helgerson Journal: Nicotine Tob Res Date: 2010-04-08 Impact factor: 4.244
Authors: Michael B Steinberg; Michelle T Bover; Donna L Richardson; Amy C Schmelzer; Jill M Williams; Jonathan Foulds Journal: Drug Alcohol Depend Date: 2010-10-16 Impact factor: 4.492
Authors: John A Stapleton; Lucy Watson; Lucy I Spirling; Robert Smith; Andrea Milbrandt; Marina Ratcliffe; Gay Sutherland Journal: Addiction Date: 2007-11-19 Impact factor: 6.526
Authors: Robert West; Witold Zatonski; Krzysztof Przewozniak; Martin J Jarvis Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-04 Impact factor: 4.254
Authors: Jennifer A Fidler; Lion Shahab; Oliver West; Martin J Jarvis; Andy McEwen; John A Stapleton; Eleni Vangeli; Robert West Journal: BMC Public Health Date: 2011-06-18 Impact factor: 3.295
Authors: Eva Kralikova; Alexandra Kmetova; Lenka Stepankova; Kamila Zvolska; Rachel Davis; Robert West Journal: Addiction Date: 2013-05-13 Impact factor: 6.526
Authors: H-J Aubin; A Bobak; J R Britton; C Oncken; C B Billing; J Gong; K E Williams; K R Reeves Journal: Thorax Date: 2008-02-08 Impact factor: 9.139
Authors: Shea Jiun Choo; Chee Tao Chang; Balamurugan Tangiisuran; Mohd Faiz Abdul Latif; Nor Aida Sanusi; Sabariah Noor Harun Journal: Int J Environ Res Public Health Date: 2022-06-24 Impact factor: 4.614
Authors: Daniel Kotz; Wolfgang Viechtbauer; Colin Simpson; Onno C P van Schayck; Robert West; Aziz Sheikh Journal: Lancet Respir Med Date: 2015-09-06 Impact factor: 30.700
Authors: Sabrina Kastaun; Jamie Brown; Leonie S Brose; Elena Ratschen; Tobias Raupach; Dennis Nowak; Constanze Cholmakow-Bodechtel; Lion Shahab; Robert West; Daniel Kotz Journal: BMC Public Health Date: 2017-05-02 Impact factor: 3.295
Authors: Gemma M J Taylor; Amy E Taylor; Kyla H Thomas; Timothy Jones; Richard M Martin; Marcus R Munafò; Frank Windmeijer; Neil M Davies Journal: Int J Epidemiol Date: 2017-12-01 Impact factor: 7.196